en
Scientific article
Open access
English

Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes

Published inScientific Reports, vol. 10, no. 1, 7073
Publication date2020
Abstract

BRCA1/BRCA2 genes play a central role in DNA repair and their mutations increase sensitivity to DNA-damaging agents. There are conflicting data regarding the prognostic value of BRCA germline mutations in breast cancer (BC) patients. We collected clinical, pathological and genetic data of a cohort 925 BC patients preselected for genetic screening and treated with neoadjuvant or adjuvant chemotherapy, of whom 266 were BRCA carriers. Overall, 171 women carried a BRCA1 mutation, 95 carried a BRCA2 mutation, and 659 were non-carriers. In the entire cohort, there was a prolonged disease-free survival (DFS) for BRCA carriers (hazard ratio (HR) = 0.63; 95% confidence interval (CI), 0.44-0.90 for BRCA1; HR = 0.72; 95%CI, 0.47-1.1 for BRCA2; p = 0.020) and a trend toward prolonged disease-specific survival (DSS; HR = 0.65; 95%CI, 0.40-1.1 for BRCA1; HR = 0.78; 95%CI, 0.44-1.38 for BRCA2; p = 0.19) though not statistically significant. In the TNBC group, BRCA carriers had prolonged DFS (adjusted HR = 0.50; 95%CI, 0.28-0.89 for BRCA1; adjusted HR = 0.37; 95%CI, 0.11-1.25, for BRCA2; p = 0.034) and DSS (adjusted HR = 0.42; 95%CI, 0.21-0.82 for BRCA1; adjusted HR = 0.45; 95%CI, 0.11-1.9 for BRCA2; p = 0.023). In the non-TNBC group, the BRCA1 or BRCA2 mutations did not have any impact on survival. These results suggest that BRCA1/BRCA2 germline mutations are associated with prolonged survival only if women were diagnosed with TNBC.

Keywords
  • Adult
  • BRCA1 Protein/genetics
  • BRCA2 Protein/genetics
  • Chemotherapy
  • Adjuvant
  • Disease-Free Survival
  • Female
  • Germ-Line Mutation
  • Humans
  • Middle Aged
  • Neoadjuvant Therapy
  • Survival Rate
  • Triple Negative Breast Neoplasms/genetics/mortality/therapy
Citation (ISO format)
DE TALHOUET, Solene et al. Clinical outcome of breast cancer in carriers of BRCA1 and BRCA2 mutations according to molecular subtypes. In: Scientific Reports, 2020, vol. 10, n° 1, p. 7073. doi: 10.1038/s41598-020-63759-1
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
ISSN of the journal2045-2322
245views
262downloads

Technical informations

Creation12/21/2020 5:03:00 PM
First validation12/21/2020 5:03:00 PM
Update time03/15/2023 11:46:19 PM
Status update03/15/2023 11:46:18 PM
Last indexation02/12/2024 12:00:20 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack